Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014
Update on safety review of Protelos / Osseor
The recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) that Protelos and Osseor should no longer be used to treat osteoporosis is still under consideration by the CHMP. At its January 2014 meeting the Committee requested additional information from the company to inform its scientific decision-making. A final opinion will be made by the CHMP at its meeting in February 2014.
Reference is made to: